GSK Tykerb Poised To Make Inroads Against Roche's Herceptin After Adding First-Line Indication
GlaxoSmithKline's orally available cancer drug Tykerb (lapatinib) is poised to make inroads against Roche's Herceptin (trastuzumab) in the fight against one of the more deadly manifestations of metastatic breast cancer in post-menopausal women
You may also be interested in...
The bundled payment pilot program resulted in a 34% decrease in overall cancer treatment costs among participating medical centers despite a 179% increase in drug spending, according to results released July 8.
SEOUL - Korea FDA approved Roche's targeted anti-cancer drug Herceptin (trastuzumab) for first-line treatment of HER2-positive metastatic gastric cancer, providing a targeted therapy for the most common and leading cancer in Korea
Firms will need to redesign sponsored links that appear on Internet search engines or forgo using them at all, food and drug attorneys suggest following the agency's recent cluster of letters citing the promotions